-
1 Comment
Ocumension Therapeutics is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.
From a valuation standpoint, the stock is 302.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 452.4.
Based on the above factors, Ocumension Therapeutics gets an overall score of 1/5.
| Industry | Biotechnology |
|---|---|
| ISIN | KYG674111011 |
| Sector | Healthcare |
| CurrencyCode | HKD |
| Exchange | HK |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | 15.24 |
| Market Cap | 7B |
| Beta | 0.89 |
| PE Ratio | None |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1477.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
